Last reviewed · How we verify
CPK dosage
CPK is a recombinant human keratinocyte growth factor used to stimulate epithelial regeneration.
CPK is a recombinant human keratinocyte growth factor used to stimulate epithelial regeneration. Used for Mucositis prevention in patients undergoing chemotherapy.
At a glance
| Generic name | CPK dosage |
|---|---|
| Sponsor | Centre Oscar Lambret |
| Drug class | Growth factor |
| Target | KGF receptor |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CPK works by binding to its receptor, which triggers a cascade of signaling events that promote the proliferation and differentiation of epithelial cells. This leads to the regeneration of damaged epithelial tissues. The exact molecular mechanisms underlying CPK's effects are complex and not fully understood.
Approved indications
- Mucositis prevention in patients undergoing chemotherapy
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
- A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (PHASE1, PHASE2)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI (PHASE1, PHASE2)
- Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels (NA)
- Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety (PHASE1, PHASE2)
- Effects of Astaxanthin Supplementation (NA)
- Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPK dosage CI brief — competitive landscape report
- CPK dosage updates RSS · CI watch RSS
- Centre Oscar Lambret portfolio CI